Michael Halstead - 01 Dec 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Dec 2022, 18:14:20 UTC
Prior SEC filing
14 Mar 2022
Next SEC filing
22 Feb 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Filing notes and source

Key filing fact

Michael Halstead filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 02 Dec 2022.

Key facts

  • This page summarizes Michael Halstead's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 02 Dec 2022, 18:14.

Change

  • Previous filing in this sequence was filed on 14 Mar 2022.
  • Current net transaction value: -$1,913,014.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ITCI transaction

Common Stock

Options Exercise

Transaction value
$773,500
Shares
+50,000
Change %
Price
$15.47
Shares after
50,000
Date
01 Dec 2022
Ownership
Direct
ITCI transaction

Common Stock

Sale

Transaction value
-$1,467,384
Shares
-27,204
Change %
-54%
Price
$53.94
Shares after
22,796
Date
01 Dec 2022
Ownership
Direct
Footnotes
F1, F2
ITCI transaction

Common Stock

Sale

Transaction value
-$1,219,130
Shares
-22,796
Change %
-100%
Price
$53.48
Shares after
0
Date
01 Dec 2022
Ownership
Direct
Footnotes
F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITCI transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
$0
Shares
-50,000
Change %
-77%
Price
$0.000000
Shares after
15,164
Date
01 Dec 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$15.47
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.68 to $54.6734, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.185 to $53.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F4

All shares underlying this option have vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .